Hims & Hers Health (NYSE:HIMS) just made a bold move to take its personalized wellness platform global. The company announced it is acquiring Eucalyptus, a leading digital health player based in Australia, in a deal worth up to $1.15 billion. The move aims to accelerate global expansion by entering Australia and Japan while strengthening its presence in the U.K., Germany, and Canada.
It also seeks to change the narrative surrounding its business, which is facing both regulatory and legal liability pressure from the federal government, as well as a patent infringement lawsuit from Novo Nordisk (NYSE:NVO) for its compounded GLP-1 drugs.
Hims stock, though, has borne the brunt of the hit, dropping about 77% from its 52-week high as investors worried that other areas of its operations — like mental health and dermatology – won’t be able to fill the gap left by weight loss.
Is This Just What the Doctor Ordered?
The deal — set to close around mid-2026 (pending approvals) — keeps things flexible financially:
- About $240 million in cash upfront.
- Guaranteed deferred payments over the next 18 months.
- Extra performance-based earnouts tied to milestones, stretching into early 2029.
These later pieces can be paid in cash or stock, giving Hims & Hers room to maneuver without straining its balance sheet.
Eucalyptus is no small add-on. It brings $450 million in annualized revenue — growing at triple-digit rates — and adds expertise in consumer healthcare. Hims & Hers plans to leverage Eucalyptus’s infrastructure to scale personalized care offerings, including telehealth and wellness products, across markets in Australia, the U.K., and Germany, with expansion underway in Japan and Canada.
Once the deal closes, Hims & Hers plans to weave in Eucalyptus’s brands, tech, and local know-how. This should let the company deliver tailored telehealth and wellness options that fit regional needs — adapting its proven U.S. direct-to-consumer approach to new audiences.
Eucalyptus’s CEO Tim Doyle will step into a Senior Vice President of International role at Hims & Hers, overseeing the combined global ops with key hubs staying in Sydney and London.
The big win here for Hims & Hers is there will be less dependence on any one market, especially amid ongoing U.S. regulatory questions.
It Won’t Be a Smooth Ride
Analysts are mostly positive about the acquisition, calling it a strong fit: it adds high-growth international revenue, diversifies the business, and eases future expansion risks. It also fits into a larger wave of global digital health growth, such as rising telehealth use, AI-powered personalization, and demand for convenient care in Europe, Asia-Pacific, and beyond.
Going international, however, brings its own hurdles: different regulations (like Europe’s tough data privacy rules), cybersecurity concerns, tech integration challenges, and competition from big tech players and local rivals. Blending the two companies smoothly will also be key to hitting those earnout targets and delivering real synergies. Acquisition integration rarely goes as planned.
While Hims & Hers’ core business remains solid, it is going to be difficult to make up for the loss of the weight-loss market in the near term. In 2024, Hims & Hers hit $1.5 billion in revenue, with non-GLP-1 segments making up over $1.2 billion. The company had guided for $2.3 billion to $2.4 billion in revenue this year, including around $725 million from weight loss, but those numbers have been scrambled.
Key Takeaway
After the GLP-1 debacle and the resulting stock slide, Hims & Hers needs a compelling next chapter. This acquisition should deliver a hefty revenue injection, fast-track global scale, and position the company as a serious player in international consumer health.
Yet execution will matter. While any big acquisition can ignite a fuse for growth, and could be the spark that gets Hims & Hers stock moving again, they are also rife with opportunity for trouble. I wouldn’t be a buyer just yet. Waiting for greater clarity on the health and wellness platform’s potential for success before buying in is the smarter play.
Top Gaining Stocks
Top Losing Stocks
